Working… Menu

Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00278486
Recruitment Status : Terminated (First subject over five years after the transplant. The second subject is not in compliance with follow ups. We do not plan to enroll more subjects.)
First Posted : January 18, 2006
Last Update Posted : April 8, 2013
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University

Brief Summary:
ARRON is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking the tissue in the retina and/or optic nerve. In addition, the disease may affect the nerves in the ear or other parts of the body . The affected nerves fail to respond, or respond only weakly, to stimuli causing numbing, tingling, pain, and progressive muscle weakness. If the nerves to the ear are affected, reduced hearing or deafness may result. The likelihood of progression of your disease is high. This study is designed to examine whether treating patients with high dose cyclophosphamide and rabbit ATG (drugs which reduce the function of the immune system) followed by return of previously collected blood stem cells will stop the progression of ARRON syndrome. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the cyclophosphamide and rabbit ATG is to destroy the cells in the immune system which are thought to be causing this disease. The purpose of the stem cell infusion is to restore the body's blood production, which will be severely impaired by the high dose chemotherapy and to produce a normal immune system that will no longer attack the body.

Condition or disease Intervention/treatment Phase
Retinal Disease Biological: Hematopoietic stem cell transplantation. Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immune Ablation and Hematopoietic Stem Cell Transplantation in Patients With Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome (Not Associated With Cancer)
Study Start Date : August 2004
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: stem cell transplantation Biological: Hematopoietic stem cell transplantation.
Autologous hematopoietic stem cell transplantation will be performed.

Primary Outcome Measures :
  1. Standard Snellen acuity clinical testing and improvement visual fields is done by using Humphrey Automated Machine with 30-2 program or using Kinetic Visual Fields on the Goldman Perimeter) [ Time Frame: 5 years after transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age between 18-60.
  2. Diagnosis of ARRON syndrome. Diagnostic criteria described below.

    Unexplained visual loss over weeks to months. The visual loss includes both visual acuity and field loss define as follows:

    • Visual acuity: 20/40 or less


    • Visual field: perimetric mean deviation -5b

      • Positive antibody to retina or optic nerve.


    A response to immunosuppressive drugs or immune modulators (response is defined by improvement of vision or decrease the rate of decline of visual loss).

    • Absence of malignancy {negative physical examination, gastrointestinal endoscopies, mammography and gynecologic examination (for female), and serum PSA measurement (for male) within a year}.
    • Negative MRI of brain.
  3. The patient has failed at least 3 months of corticosteroids (prednisone 0.5mg/kg to start), IVIG and at least one other immunosuppressive drug such as methotrexate, Imuran, cyclosporine, etc. Failure is defined by decline of visual acuity (by standard Snellen acuity clinical testing) or visual field (by Humphrey Automated Machine with the 30-2 program or using Kinetic Visual Fields on the Goldman Perimeter)

Exclusion Criteria:

  1. Absence of light perception lasting more than 6 months
  2. Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy.
  3. Prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix. Other malignancies for which the patient is judged to be cured, such as head and neck cancer, or breast cancer will be considered on an individual basis.
  4. Positive pregnancy test.
  5. Inability or unwillingness to pursue effective means of birth control. Effective birth control is defined as 1) refraining from all acts of vaginal intercourse (ABSTINENCE); 2) consistent use of birth control pills; 3) injectable birth control methods (Depo-provera, Norplant); 4) tubal sterilization or male partner who has undergone vasectomy; 5) placement of an IUD (intrauterine device); or 6) use, with every act of intercourse, of diaphragm with contraceptive jelly and/or condoms with contraceptive foam.
  6. Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.
  7. FEV1/FVC < 60% of predicted after bronchodilator therapy (if necessary).
  8. DLCO < 50% of predicted.
  9. Active ischemic heart disease and/or those who have had a myocardial infarction within 6 months.
  10. Resting LVEF < 40 %.
  11. Bilirubin > 2.0 mg/dl
  12. Serum creatinine > 2.0 mg/dl.
  13. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron compounds/medications.
  14. Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams.
  15. Diagnosis of primary progressive MS.
  16. Platelet count < 100,00/ul
  17. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with treatment or informed consent impossible.
  18. Active infection except asymptomatic bacteruria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00278486

Layout table for location information
United States, Illinois
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Richard Burt, MD
Layout table for investigator information
Principal Investigator: Richard Burt, MD Northwestern University

Layout table for additonal information
Responsible Party: Richard Burt, MD, MD, Northwestern University Identifier: NCT00278486     History of Changes
Other Study ID Numbers: DI ARRON 04
First Posted: January 18, 2006    Key Record Dates
Last Update Posted: April 8, 2013
Last Verified: April 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Eye Diseases